, Volume 11, Issue 6, pp 355-356
Date: 17 Aug 2012

Dronedarone

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Whilst tremendous advances have been made in the treatment of coronary artery disease, hypertension, and heart failure, the optimal management of atrial fibrillation (AF) still remains a challenge.[1] Furthermore, the prevalence of AF is increasing in developed countries due to aging of the general population, and this arrhythmia affects more than 8% of patients over 80 years of age.[2]

Treatment of AF has two major goals: symptom relief and prevention of complications such as thromboembolic events and heart failure. Given that AF commonly co-exists with multiple co-morbidities — essentially cardiovascular risk factors — there is no surprise that sub-optimal control of cardiovascular risk factors translates to the subsequent development of AF.[3] Also, AF leads to an increased risk of mortality and hospitalizations, the latter resulting in a high healthcare cost burden.[4,5] Hospitalizations are also a surrogate for subsequent mortality in AF patients.[6]

Nonetheless, AF represents a maj